Published February 9, 2018
| Version v1
Report
Open
Western Blotting NSD3: Further Testing of Commercial Antibodies
Description
SGC Open Notebook Project to Characterize the HMTase NSD3
Exp012 Objective: To test commercial antibodies to NSD3 by western blotting whole cell lysates from cancer cell lines, predominately of an AML background. Validated antibodies will be used as tools to study NSD3’s function on chromatin.
Notes
Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
Files
exp012.pdf
Files
(571.6 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:69bc48aba8569c465490c0a0f37fd1cb
|
571.6 kB | Preview Download |